Analysis of microarray data [26] obtained from mouse neuroblastoma tumors bearing the human MYCN transgene further corroborated that GLS2 expression was significantly elevated during aggressive tumor progression (Figure 7B). The gene discussed is GLS2; the disease is neuroblastoma.